Immunobiologics
Biologic therapies (immunobiologics) are the biggest breakthrough of modern medicine in treating chronic inflammatory and autoimmune skin disease. Classic systemic treatments (corticosteroids, cyclosporine, methotrexate) suppress the immune system broadly and carry significant organ toxicity. Biologics, by contrast, are monoclonal antibodies (mAbs) or receptor-binding fusion proteins made with recombinant DNA technology. They recognize and neutralize their targets with very high molecular precision, acting directly on specific pro-inflammatory cytokines, membrane receptor chains or surface markers on immune cells.
In clinical dermatology, unraveling the role of the Th17 axis (IL-23/IL-17) in psoriasis, the Th2 axis (IL-4/IL-13) in atopic dermatitis, IgE in chronic urticaria and B cells (CD20) in pemphigus has opened the era of targeted therapy. At Haute-Derma, our biologic protocols follow international standards and include thorough safety screening, aiming for maximal skin clearance (PASI 90–100, EASI 75–90) while minimizing effects on the rest of the body.
Biological Mechanisms and Pharmacodynamics of Monoclonal Antibodies
Targeted Molecular Blockade
Humanized or fully human recombinant monoclonal antibodies bind their biological targets with very high affinity and specificity:
- Neutralizing free cytokines: The antibody binds a pro-inflammatory cytokine circulating in tissue fluid or blood, preventing it from attaching to its receptor on target cells.
- Receptor blockade: The antibody occupies the receptor on the cell membrane, preventing the intracellular signaling cascade from starting.
- Antibody- and complement-dependent cytotoxicity (ADCC/CDC): The antibody binds a surface marker (such as CD20), directing the immune system to selectively destroy the disease-driving cell population.
Key Immune Pathways in Dermatology
- IL-23 / Th17 / IL-17 axis (psoriasis and psoriatic arthritis): Dendritic cells secrete IL-23, which sustains the differentiation and survival of Th17 cells. Th17 cells release IL-17A and IL-17F, driving explosive keratinocyte proliferation and the release of chemokines that recruit neutrophils, forming pustules and psoriasis plaques.
- Th2 / IL-4 / IL-13 axis (atopic dermatitis and prurigo nodularis): IL-4 and IL-13 released by Th2 cells reduce filaggrin and loricrin production (breaking down the skin barrier), directly activate itch-sensing C nerve fibers, and drive B cells to class-switch to IgE production.
- CD20 on B cells (pemphigus vulgaris): Mature B cells produce anti-desmoglein 1 and 3 autoantibodies that break the connections between epidermal cells (acantholysis). Targeting CD20 eliminates these autoreactive B cells.
Classes of Biologic Drugs in Clinical Use
- Anti-IL-17: secukinumab and ixekizumab (selective IL-17A blockade), bimekizumab (dual IL-17A and IL-17F blockade). Very rapid clearance of psoriasis.
- Anti-IL-23: guselkumab, risankizumab, tildrakizumab (targeting the p19 subunit of IL-23). High rates of skin clearance with long-lasting effect (injections every 8–12 weeks).
- Anti-IL-4 / IL-13 (anti-IL-4Rα and anti-IL-13): dupilumab (binds IL-4Rα, blocking both IL-4 and IL-13) and tralokinumab (selective IL-13 blockade). A landmark in treating moderate-to-severe atopic dermatitis.
- Anti-TNF-α: adalimumab, infliximab, etanercept. Used for psoriasis, psoriatic arthritis and hidradenitis suppurativa.
- Anti-IgE: omalizumab. The preferred option for chronic spontaneous urticaria (CSU) that does not respond to high-dose antihistamines.
- B-cell depletion (anti-CD20): rituximab. A first-line option that achieves complete remission in most patients with autoimmune blistering pemphigus.
Comparison of Pharmacology and Indications
| Drug (Generic) | Drug Class / Molecular Target | Preferred Indications |
|---|---|---|
| Dupilumab | Anti-IL-4Rα / alpha chain of the IL-4 receptor | Moderate-to-severe atopic dermatitis, prurigo nodularis |
| Secukinumab | Anti-IL-17A / free IL-17A | Plaque psoriasis, psoriatic arthritis |
| Guselkumab | Anti-IL-23 / p19 subunit of IL-23 | Moderate-to-severe plaque psoriasis |
| Omalizumab | Anti-IgE / free circulating IgE | Chronic spontaneous urticaria (CSU) |
| Rituximab | Anti-CD20 / CD20 on B cells | Severe pemphigus vulgaris / foliaceus |
Managing Biologic Toxicity, Safety and Pre-Treatment Screening
Although biologics are much safer than classic systemic drugs, treatment still requires careful control of systemic risks:
- Reactivation of latent infections (latent TB and hepatitis B): The risk is highest with anti-TNF-α and anti-CD20 drugs. TNF-α is central to forming the granulomas that wall off Mycobacterium tuberculosis. Blocking TNF-α can break down these granulomas and trigger disseminated TB.
- Anti-drug antibodies (ADA): The immune system may recognize the biologic as a foreign protein and make ADAs, which neutralize the drug or speed its clearance, leading to secondary loss of response.
- Triggering inflammatory bowel disease (IBD): IL-17 helps protect and maintain the gut mucosal barrier. Anti-IL-17 drugs (secukinumab, ixekizumab) can trigger or worsen Crohn's disease or ulcerative colitis.
- Mucosal Candida infection: With IL-17 suppressed, local defense against yeasts weakens, increasing the rate of oral or vaginal Candida infection (usually mild to moderate and responsive to topical or oral fluconazole).
Treatment Process at Haute-Derma
Mandatory Pre-Biologic Screening
- TB screening: QuantiFERON-TB Gold (or T-SPOT.TB) blood test plus a chest X-ray. If latent TB is found, preventive isoniazid treatment is required for at least 1 month before the first biologic dose.
- Hepatitis and HIV screening: HBsAg, total anti-HBc, anti-HCV and HIV Ab/Ag.
- General assessment: Complete blood count (CBC), liver and kidney function, CRP and lipid panel.
- Vaccinations: Complete inactivated vaccines (influenza, pneumococcal, hepatitis) before treatment. Live attenuated vaccines (such as varicella and MMR) are strictly contraindicated during biologic therapy.
Loading Dose and Individualized Maintenance
- Subcutaneous (SC) injections are given with proper technique in the abdomen, thigh or upper arm, following the loading schedule to quickly reach effective steady-state trough concentrations.
- Patients are shown how to monitor injection-site reactions (redness, swelling, mild pain), which usually settle on their own within 24–48 hours.
Response Assessment and Regular Monitoring
- Severity scores (PASI for psoriasis; EASI/DLQI for atopic dermatitis) are assessed at weeks 12 and 16.
- Clinical targets: PASI 90/100 or EASI 75/90.
- If the response fades over time because of ADAs, the doctor will consider optimizing the dose (shortening the interval) or switching to a biologic with a different mechanism.
